

## A case of PERM (Progressive Encephalomyelitis with Rigidity and Myoclonus) anti-GlyR

### positive C Davassi, G Fragiotta, M Serrao, D Di Lenola, G Coppola, C Casali, F Pierelli

"Sapienza" University of Rome Polo Pontino, Department of medico-surgical sciences and biotechnologies, Latina, Italy

Introduction: Progressive Encephalomyelitis with Rigidity and Myoclonus, (PERM) also called stiff-person syndrome plus, is similar to stiff-person syndrome with rigidity, stimulus-sensitive spasms, myoclonus, hyperekplexia autonomic disturbance, but with additional brainstem or other and neurological defects.

It has been historically associated with antiGAD antibodies. Since 2008, when a patient negative for antiGAD antibodies was found to have anti-glycine receptor antibodies (GlyR), further patients with PERM were investigated for them and correlation between these antibodies and PERM has been confirmed.

INR		Value	Normal ranges
	INR		0.90-1.20
PTT		30.3 sec.	25-35 sec.
Fibrinogen		396 mg/dl	200-400 mg/dl
Anticardiolipine IgG		<3 GPLU/ml	0-15 GPLU/ml
Anticardiolipine IgM		<3 MPLU/ml	0-15
Lupus like anticoagular	nt (LAC)	1.1 RATIO	>2.0 present 1.5-2 mod. Present 1.2-1.5 weakly Present
			<1.2 absent
Anti Acetilcoline receptor		0.30 nmol/L	<0.25 negat 0.25-0.40 doubt > 0.40 positive
Anti-ENA antibodies pr	ofile		
nRNP/Sm		Negative	
SSA RO-52		Negative	
SSB(La)		Negative Negative	
Scl 70		Negative	
Jo-1		Negative	
ANA		Negative	
Anti-DNA antibodies		Negative	
NSE (neuron-specific enolase)		8,4 ng/ml	4,7 – 14,7 ng/ml
Alpha-fetoprotein		1,3 ng/ml	0,0 – 8,1 ng/ml
CA125		8,4 U/ml	0 – 30,2 U/ml
CA15-3		17,3 U/ml	0 – 32,4 U/ml
Ca 19-9		8,73 U/ml	0 – 37 U/ml
CEA PSA		1,03 ng/ml	0 – 5,0 ng/ml 0 – 4 ng/ml
TSH		0,58 ng/ml 1,144 microUI/ml	0 – 4 ng/ml 0,35 – 5,0 microUI/ml
Table 2 Examination		Value	Normal ranges
Anti-Ma1 antibodies		Negative	
Anti-Ma <sup>2</sup> /Ta antibodies		Negative	
Anti-Ma2/ Ta antibodies Anti-CV2 (CRMP5) antibodies		Negative	
Anti-Yo antibodies		Negative	
Anti-HU antibodies		Negative	
Anti-Ri antibodies		Negative	
Anti-amphiphysin antibodies		Negative	
Anti-GABA B1 antibodi	es	Negative	
Reuma-TEST		0,9 IU/ml	0,0 – 20 IU/ml
Anti- GAD antibodies	<u>,</u>	0,4 U/ml	0,0 – 5,0 U/ml
Anti-neutrophil antibodies (c-ANCA)	cytoplasmic	Negative	
Anti-neutrophil	cytoplasmic	Negative	
antibodies (p-ANCA) Anti-MAG IgM		230,6 BTU	0,0 – 1.000 BT
Anti-ganglioside antibo GM1 antibodies	dies IgG	Negative	
GM2 antibodies		Negative	
GM3 antibodies		Negative	
		Negative	
GD1a antibodies		Negative	
		-	
GD1b antibodies GT1b antibodies		Negative	
GD1b antibodies GT1b antibodies GQ1b antibodies			
GD1b antibodies GT1b antibodies GQ1b antibodies Anti-ganglioside antibo	dies IgM	Negative Negative	
GD1b antibodies GT1b antibodies GQ1b antibodies Anti-ganglioside antibo GM1 antibodies	dies IgM	Negative	
GD1b antibodies GT1b antibodies GQ1b antibodies Anti-ganglioside antibo GM1 antibodies GM2 antibodies	dies IgM	Negative Negative Negative	
GD1b antibodies GT1b antibodies GQ1b antibodies Anti-ganglioside antibo GM1 antibodies GM2 antibodies GM3 antibodies GD1a antibodies	dies IgM	Negative Negative Negative Negative Negative	
GD1b antibodies GT1b antibodies GQ1b antibodies Anti-ganglioside antibo GM1 antibodies GM2 antibodies GM3 antibodies GD1a antibodies GD1b antibodies	-	Negative Negative Negative Negative Negative Negative	
GD1b antibodies GT1b antibodies GQ1b antibodies Anti-ganglioside antibo GM1 antibodies GM2 antibodies GM3 antibodies GD1a antibodies GD1b antibodies GT1b antibo	-	Negative Negative Negative Negative Negative Negative Negative Negative	
GD1b antibodies GT1b antibodies GQ1b antibodies Anti-ganglioside antibo GM1 antibodies GM2 antibodies GM3 antibodies GD1a antibodies GD1b antibodies GT1b antibo	-	Negative Negative Negative Negative Negative Negative	
GD1b antibodies GT1b antibodies GQ1b antibodies Anti-ganglioside antibo GM1 antibodies GM2 antibodies GM3 antibodies GD1a antibodies GD1b antibodies GT1b antibo	-	Negative Negative Negative Negative Negative Negative Negative Negative Negative	
GD1b antibodies GT1b antibodies GQ1b antibodies Anti-ganglioside antibo GM1 antibodies GM2 antibodies GM3 antibodies GD1a antibodies GD1b antibodies GT1b antibo	-	Negative Negative Negative Negative Negative Negative Negative Negative Negative	Normal ranges
GD1b antibodies GT1b antibodies GQ1b antibodies Anti-ganglioside antibo GM1 antibodies GM2 antibodies GM3 antibodies GD1a antibodies GD1b antibodies GT1b antibo	-	Negative Negative Negative Negative Negative Negative Negative Negative	Normal ranges 120 – 970 pg/ml
GD1b antibodies GT1b antibodies GQ1b antibodies Anti-ganglioside antibo GM1 antibodies GM2 antibodies GM3 antibodies GD1a antibodies GD1b antibodies GT1b antibo GQ1b antibodies	-	Negative Negative Negative Negative Negative Negative Negative Negative	-
GD1b antibodies GT1b antibodies GQ1b antibodies Anti-ganglioside antibo GM1 antibodies GM2 antibodies GM3 antibodies GD1a antibodies GD1b antibodies GT1b antibo GQ1b antibodies Folic acid	-	Negative Negative Negative Negative Negative Negative Negative Negative Negative Value	120 – 970 pg/ml
GD1b antibodies GT1b antibodies GQ1b antibodies Anti-ganglioside antibo GM1 antibodies GM2 antibodies GM3 antibodies GD1a antibodies GD1b antibodies GT1b antibo GQ1b antibodies Folic acid Alpha-fetoprotein	-	Negative Negative Negative Negative Negative Negative Negative Negative Negative Value	120 – 970 pg/ml 1,5 – 16,9 ng/ml
GD1a antibodies GD1b antibodies GT1b antibodies GQ1b antibodies GQ1b antibodies Anti-ganglioside antibo GM1 antibodies GM2 antibodies GD1a antibodies GD1b antibodies GD1b antibodies GQ1b antibodies Fable 3 Examination Vitamin B12 Folic acid Alpha-fetoprotein CA125 CA15-3	-	Negative Negative Negative Negative Negative Negative Negative Negative Negative Value 209 pg/ml 2,1 ng/ml 3,44 ng/ml	120 – 970 pg/ml 1,5 – 16,9 ng/ml 0,0 – 6,0 ng/ml

Materials and Methods: We report a case of a 74-year-old Caucasian man who first presented with severe dysphagia and hypophonia. His past medical history was unremarkable except for a progressive sleep disorder. Routine blood tests, neck and chest CT were all negative. Brain MRI showed small ischaemic lesions. Lanryngoscopy showed left vocal cord palsy. Patient received corticosteroids until full recovery of dysphagia and mild improvement of hypophonia. Eight months later he showed severe leg stiffness, jerks and paresthesias. Neurological evaluation revealed bilateral equinus foot and severe gait disturbance due to leg rigidity. CNS MRI and blood tests were unremarkable. After another course of steroids his symptoms improved, but he subsequently presented a relapse of his leg rigidity with painful cramps. ENG/EMG detected subcontinual motor activity, with lack of muscle relaxation in the gastrocnemii. Autoimmune work-up, including anti-GABA B and anti-GAD antibodies, resulted negative as well as oncomarkers (tables 1, 2, 3). After five months the patient complained severe deterioration of leg stiffness, dyplopia, dysphagia and dysphonia. Neurological evaluation revealed asymmetry of smiling, right eye esotropia, left deviation of protruted tongue, left curtain sign and severe leg stiffness. He repeated routine blood tests, and a CSF examination was performed, resulting all unremarkable. In suspicion of PERM we looked for anti-Glyα1R antibodies in both plasma and CSF. We initiated IVIg followed by corticosteroids.

Results and Discussion: almost complete regression of the symptoms was observed, with recovery of gait and swallowing. Anti-Glyα1R antibodies resulted positive at low titer in both plasma and CSF. Since 2008, when a patient with PERM was found to be positive to anti-Glyα1R, other similar patients have been described (1). GlyR is a pentameric gated ion channel and its activation by glycine leads to hyperpolarization of the membrane potential and reduced excitation (1). Its blockage by the anti-Glyα1R antibodies interfere with the mechanisms of motor and sensory excitation as well as with several other pathways, so that neurological signs appear.

Conclusions: anti-GlyR antibodies should be searched for in patients with

brainstem dysfunction, hyperekplexia, stiffness, rigidity, myoclonus and

spasms, due to the potential recovery after immunomodulating therapy, that

#### References

must be initiated (1).

1. Carvajal-Gonzalez A1, Leite MI, Waters P, Woodhall M, Coutinho E, Balint B, Lang B, Pettingill P1, Carr A, Sheerin UM, Press R, Lunn MP, Lim M, Maddison P, Meinck HM, Vandenberghe W, Vincent A.Glycine receptor antibodies in PERM and related syndromes: characteristics, clinical features and outcomes. Brain. 2014 Aug;137(Pt 8):2178-92. doi: 10.1093/brain/awu142. Epub 2014 Jun 20.



### XLVI CONGRESSO NAZIONALE 10-13 OTTOBRE 2015 – GENOVA

# WebPoster



